Index

acetylcholine 98
acetylcholinesterase inhibitors 184
AD see Alzheimer's disease; antidepressants
adherence to medication 118, 167
adolescents
anxiety 30
diagnosis of depression 82
suicidality 78, 81, 82, 85
treatment of depression 85
see also children
AEDs see antiepileptic drugs
age
depression in MS 162
suicidality 52
almotriptan 100
Alzheimer's disease (AD) and depression 177–87
case study 186
comorbidity 4–5, 6, 179, 182–3
course of AD 181–2
diagnosis
of AD 178–9
of depression 45, 179–81, 182
neuropathology 178
prevalence 44, 179
subtypes 181
suicidality 56
symptoms
of AD 177–8, 182
of depression 179, 180
treatment 100, 183–4
amitriptyline 98, 111–12
Ammon's horn 12, 13
amygdala 11, 23–4, 31, 78
neural pathways 13–15
amyloid-associated depression 183
amyotrophic lateral sclerosis (ALS) 56–7
antidepressants (ADs) 94–101
adverse effects
MAOIs 96
sedation 98
SNRIs 111
SSRIs 99, 111, 136, 137, 185
TCAs 98, 100, 111
in anxiety 31
in children 85
in children 85
classes 94–9
see also individual classes
cognition and 67–8
drug–drug interactions 98, 99, 100, 136–7
guidelines for use 32–4
mechanisms of action
cytokines 22–3
growth factors 19, 20
neurotransmitters 16, 18, 94–7
in neurologic disorders
dementia 100, 183–4
epilepsy 100–1, 130, 135–7
Huntington's disease 150
migraine 99–100, 111–12
MS 100, 167–8
PD 100, 149–50
stroke 120–1
TBI 199–200
response rates 33–4, 97
antiepileptic drugs (AEDs)
adverse effects 81, 137
depression 132, 135
suicidality 56, 127–8
interactions with antidepressants 136–7
in migraine 111, 112
antiepileptic surgery 6, 56, 135
antihypertensive drugs 18, 112
antiparkinsonian drugs 149
antipsychotic drugs 34
anxiety disorders 30–1
in children and adolescents 30, 78, 79, 81, 82, 85
and epilepsy 78, 129, 134, 135
and migraine 106, 112
and PD 46, 147
screening/diagnosis 40, 59, 84, 135
and TBI 79
treatment 34, 85
apathy 147, 182
aphasia 44
aripiprazole 150
arrhythmias 117
attention deficit hyperactivity disorder (ADHD) 79, 81
atypical depression 41, 94, 133
BAD see bipolar affective disorder
barbiturates 128, 132, 137
BDNF (brain-derived neurotrophic factor) 11, 19–20
Beck Depression Inventory-II (BDI-II) 41, 42, 46, 59, 109, 164
Beck Depression Inventory-Fast Screen (BDI-FS) 42, 43–4
beta blockers 111, 112
bipolar affective disorder (BAD)
definition 30
and migraine 106, 107

Depression in Neurologic Disorders: Diagnosis and Management, First Edition.
Edited by Andres M. Kanner.
© 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
bipolar affective disorder (cont'd) and MS 158–9
screening/diagnosis 32
treatment 34, 137–8
bleeding disorders 99, 117
bone mineral density, reduced 137
brain anatomy see neuroanatomy
brain trauma see traumatic brain injury
brain tumors 79–80, 83
brain-derived neurotrophic factor (BDNF) 11, 19–20
bupropion 96–7, 99, 136
buspirone 200
cAMP signaling pathway 11, 18, 19–20
cardiovascular disease 30, 100, 117
CBT see cognitive–behavior therapy
Center for Epidemiological Studies Depression Scale (CES-D) 41, 42, 164
children 77–87
brain tumors 79–80, 83
diagnosis of depression 80–3
epilepsy 77, 78–9, 83, 86
MS 78, 80, 160
neurobiology 78–80
neurofibromatosis 78, 80
suicidality 78, 81, 82, 85
TBI 78, 79
treatment of depression 83–6
cingulate gyrus 7, 23, 149
citalopram 96, 136, 185, 199
classification of mood disorders 29–30
clinical interviews 40, 69
with children 82
in dementia 180
in MS 164
clomipramine 98, 136
cogulation disorders 99, 117
cognitive impairment assessment 68
in children 83
in depression 65–7, 74–5
after treatment 67–8
depressive pseudodementia 183
in MS 165
and screening for depression 40
in stroke 120
cognitive–behavior therapy (CBT) 32
in children 85–6
in epilepsy 137
in migraine 112–13
in MS 169
in TBI 200–1
compliance with medication 118, 167
Cornell Scale for Depression and Dementia (CSDD) 45, 181
corticosteroids
HPA hyperactivity 11, 19, 117, 132–3
treatment of MS 167
corticotrophin-releasing factor (CRF) 19
CREB (cAMP response element-binding protein) 11, 18
CSDD (Cornell Scale for Depression and Dementia) 45, 181
cytokines 20–3
and MS 163
and stroke 118
DA see dopamine (DA)/dopaminergic system
death, fear of, in children 81
deep brain stimulation (DBS) 23, 34
in PD 146, 150–1
dementia see Alzheimer's disease (AD) and depression
depressive pseudodementia 183
desipramine 22, 98
dextroamphetamine 200
diabetes mellitus 117–18
diagnosis of depression
case studies 71–4, 86
in children 80–3
DSM-IV definitions 29–30
in the presence of
dementia 45, 179–81, 182
epilepsy 41–2, 133–5
Huntington's disease 147
migraine 107
MS 42–3, 158–9, 163–5
PD 46, 146–7, 152
stroke 43–4, 119–20
TBI 190, 194
psychometric tools 31, 32, 39–40, 47, 70–1
dopamine agonists in PD 149, 150
dopamine (DA)/dopaminergic system 17–18, 95
in migraine 110
in PD 147, 148
dorsolateral prefrontal cortex 7
dual-serotonin 2 antagonists/serotonin reuptake inhibitors (SARIs) 97, 99, 199
dysthymic disorder 29, 41, 159
EAAT proteins (excitatory amino acid transporters) 131
economic costs 28, 177, 189
EDSS (Expanded Disability Status Scale) 160, 161
elderly patients
idiopathic depression 34–5
stroke 43–4
see also Alzheimer's disease and depression
electroconvulsive therapy (ECT) 34
in dementia 184
in PD 150
in TBI 201
emotional lability 159, 182
epidemiology
anxiety and depression 30
dementia and depression 44, 179
depression alone 28, 158, 189–90
epilepsy and depression 3, 40, 126–7
Huntington's disease and depression 147
migraine and depression 105–6
MS 157–8
MS and depression 42, 158, 159–60, 161–2
PD and depression 3, 45–6, 146
poststroke depression 43, 116
suicidality 52–3
TBI and depression 190–4
epilepsy and depression 126–39
and anxiety 78, 129, 134, 135
case study 138
in children and adolescents 77, 78–9, 83, 86
comorbidity 4, 6, 129–30
course of epilepsy 6, 127, 135
Index

diagnosis 41–2, 133–5
HPA axis 132–3
migraine as a risk factor 109–10
neuroanatomy 78–9, 129, 133
neurotransmitters 16–17, 130–2
prevalence 3, 40, 126–7
quality of life 128–9
and suicidality 55–6, 127–8
symptoms 133–4
treatment 100–1, 130, 135–8

escitalopram 96, 136, 185, 199

England 57
excitatory amino acid transporters (EAAT-1 to EAAT-4) 131
executive functioning deficits 65–6, 177
Expanded Disability Status Scale (EDSS) 160, 161
extrapyramidal symptoms 99

fatigue in MS 165
Fatigue Severity Scale 164
financial costs 28, 177, 189
fluoxetine 99
in children 85
CYP isoenzymes and 136
in dementia 185
in migraine 111
in poststroke depression 121
fluvoxamine 99, 136
forix 12, 13
frontal lobe see prefrontal cortex
functional neuroimaging 24
in movement disorders 148

gabapentin 111, 112
GAD see generalized anxiety disorder; glutamic acid decarboxylase
γ-aminobutyric acid (GABA)/GABAAergic system 18, 132, 147
GDS (Geriatric Depression Scale) 43, 45, 46
gender
MS 161
suicidality 52
generalized anxiety disorder (GAD) 31, 84, 135
see also anxiety disorders
Generalized Anxiety Disorder-7 (GAD-7) questionnaire 40, 59, 135

-genetics
Huntington's disease 148
impact of testing 55
migraine 110
PD 148
pharmacogenetics 19
serotonergic system 17
suicidality 53
Geriatric Depression Scale (GDS) 43, 45, 46
glatiramer acetate 166
glial cells 7, 11

-glucocorticoids
HPA hyperactivity 11, 19, 117, 132–3
treatment of MS 167

-glutamate/glutamatergic system 130–1

-gray matter, reduced volume 10–11, 23, 133

HADS (Hospital Anxiety and Depression Scale) 43, 46, 109
Hamilton Depression Rating Scale (HAM-D) 43, 45, 46, 147
HD see Huntington's disease
headaches see migraine
Health of the Nation Outcome Scale (HoNOS) 45

-hippocampus
cortisol and 132
depression and 19, 20, 21
in epilepsy 78
in MS 163
neural pathways 12–13
reduced volume 11, 23, 31

Hospital Anxiety and Depression Scale (HADS) 43, 46, 109
HPA (hypothalamic–pituitary–adrenal) axis 11, 19, 117, 132–3

-5-HT (5-hydroxytryptamine) see serotonin/serotonergic system
Huntington's disease (HD) and depression 152
comorbidity 54–5, 147
diagnosis 147

-genetics
impact of testing 55

-neuroanatomy 148, 149

-prevalence 147
suicidality 55, 147
treatment 150, 151

-5-hydroxytryptamine (5-HT) see serotonin/serotonergic system
hypertension 117
hypnotilmsic–pituitary–adrenal (HPA) axis 11, 19, 117, 132–3

-iatrogenic causes of depression
in epilepsy 56, 127–8, 135
in MS 167

-IDD see interictal dysphoric disorder
idiopathic depressive disorders 28–35, 194–5
classification 29–30
comorbidities 30–1
diagnosis 31, 32
treatment 31–5
impramine 98

-immune/inflammatory processes 20–3
in MS 163
in stroke 118

-interferons (IFN) 22
in MS 100, 163, 166–7

-interictal dysphoric disorder (IDD)
in epilepsy 41, 133
and migraine 107, 112

-Intercital Dysphoric Disorder Inventory (IDDI) 42

-interleukins (IL) 20, 21, 22, 118

-interviewing patients 40, 69
children 82
with dementia 180
with MS 164

-see also psychometric tests
irreversible monoamine oxidase inhibitors (IMAOIs) 95, 96

-ketamine 131

-lamotrigine 112
levodopa 149
locus coeruleus (LC) 17, 148

-MADRS (Montgomery–Åsberg Depression Rating Scale) 46, 147
magnetic resonance imaging (MRI) 10–11, 23–4
major depressive disorder (MDD), definition 29–30
mania 30
MAOIs (monoamine oxidase inhibitors) 18, 94–6, 97–8, 149
maprotyline 136
MDQ (Mood Disorder Questionnaire) 32, 109
memory loss 66, 166, 177, 178
methylphenidate 200
migraine and depression 105–13
case study 105
comorbidity 4, 105–6
course of migraine 109–10
diagnosis of depression 107
of migraine 108
pathogenic mechanisms 110
quality of life 169
and suicidality 57, 165, 167
treatment of depression 100, 167–9
of MS 165–7
Multiple Sclerosis Severity Score 164–5
NaSSA antidepressants 97
natalizumab 166
NDDI-E (Neurological Disorders Depression Inventory for Epilepsy) 41, 134
NDRI antidepressants 96–7, 99
NE see norepinephrine (NE)/norepinephrinergic system
nefazodone 97
neuroanatomy in Alzheimer’s disease 178
in anxiety 31
in children 78–9, 80
in depression 7, 10–11, 23–5, 65
in epilepsy 78–9, 129, 133
in Huntington’s disease 147–8, 149
in MS 162–3
normal 11–16
in PD 148–9
in TBI 79, 197–8
neuroimmune theory of depression 20–3
Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) 41, 134
neuropsychological evaluation 64–75
case studies in differential diagnosis 71–4
in children 82–3, 85
cognitive performance in depression 65–7
after treatment 67–8
in dementia 45, 180–1
methods 69–71
see also clinical interviews; psychometric tools
in MS 163–4
referred for 68–9
neurotransmitters 16–18
antidepressants and 16, 18, 94–7, 98
cortisol and 132
in epilepsy 16–17, 130–2
in migraine 110
monoaminergic theory of depression 18–19
in PD 147, 148
neurotrophic theory of depression 19–20
noncompliance with medication 118, 167
noradrenergic and specific serotonergic antidepressants (NaSSAs) 97
norepinephrine and dopamine reuptake blockers (NDRIs) 96–7, 99
norepinephrine (NE)/norepinephrinergic system 17
obsessive–compulsive disorder 79, 84, 85
orbitofrontal cortex 7, 132–3
osteopenia/osteoporosis 137
P-glycoprotein 18–19
panic disorder 106
PARK genes 148
Parkinson’s disease (PD) and depression 145–6, 152
case study 151–2
comorbidity 5, 6, 45–6, 146, 147
diagnosis 46, 146–7, 151–2
genes 148
neuroanatomy 148–9
prevalence 3, 45, 146
quality of life 45, 146
and suicidality 46, 54, 146
Index · 211

symptoms 146, 147

treatment 100, 149–51

paroxetine 99, 136, 185, 199

pathological affect 159, 182

Patient Health Questionnaire-2 (PHQ2) 42–3

Patient Health Questionnaire-9 (PHQ9) 40

PD see Parkinson's disease

peri-ictal depression 134

pharmacogenetics 19

phobias 84

physician-assisted suicide 57

platelet disorders 99, 117

positron emission tomography (PET) 24

in movement disorders 148

postictal depression 42, 55, 127, 134

poststroke depression (PSD) see stroke and depression

Poststroke Depression Scale (PSDS) 44

posttraumatic stress disorder (PTSD) 79, 84

pramipexole 150

prefrontal cortex 7, 11, 23–4

in anxiety 31

cognition and 65–6

neural networks 15–16

in TBI 79, 198

prevalence see epidemiology

propranolol 111, 112

pseudobulbar affect 159

psychological evaluation see neuropsychological evaluation

psychometric tools for diagnosis of anxiety 40, 59, 135

for diagnosis of depression 31, 32, 39–40, 46–7, 70–1

in children 82

in dementia 45, 180–1

in epilepsy 41–2, 134–5

in Huntington's disease 147

in migraine 109

in MS 42–3, 164

in PD 46, 147

in stroke 43–4

suicidality 59

in TBI 190

psychotherapy 32

in children 85–6

in dementia 184

in epilepsy 137

in migraine 112–13

in MS 168–9

in PD 150

in TBI 200–1

psychotic disorders 34, 137

PTSD (posttraumatic stress disorder) 79, 84

quality of life in children and adolescents 77–8

in epilepsy 128–9

in migraine 108–9

in MS 168–9

in PD 45, 146

questioning patients see interviewing patients

raphe nuclei 16, 148

reboxetine 96, 99

reversible inhibitors of monoamine oxidase A (RIMAs) 95, 96, 97–8

riluzole 131

risk factors for dementia 178

depression a risk factor for dementia 4–5, 182–3

for epilepsy 4, 129

for migraine 4, 106

for PD 5

for stroke 4, 116–17

for depression in TBI 198

for epilepsy 4, 109–10, 129–30

for suicidality 52–3, 82

rizatriptan 100

Rorschach inkblot test 70

Rush Postictal Psychiatric Symptoms Questionnaire 42

SADQ (Stroke Aphasic Depression Questionnaire) 44

SARI antidepressants 97, 99, 199

SCID (Structured Clinical Interview for DSM-IV Axis 1 Disorders) 31

screening instruments for anxiety 40, 59, 84, 135

screening instruments for depression 31, 32, 39–40, 46–7, 70–1

in children 82

in dementia 45, 180–1

in epilepsy 41–2, 134–5

in Huntington's disease 147

in migraine 109

in MS 42–3, 164

in PD 46, 147

in stroke 43–4

suicidality 59

in TBI 190

screening instruments for disability in MS 161, 164–5

selective norepinephrine reuptake inhibitors (NRIs) 96, 99

selective serotonin reuptake inhibitors (SSRIs) 33, 96, 98–9

in children 85

CYP isoenzymes and 136

in dementia 184, 185

in epilepsy 130, 135–7

in migraine 111, 112

in MS 167–8

in PD 149–50

in poststroke depression 121

in TBI 199

selegiline 149

separation anxiety disorder 81, 84

serotonin (5-HT)/serotonergic system 16–17

antidepressants and 16, 94–5, 96, 97, 98

cortisol and 132

in epilepsy 16–17, 130

in migraine 110

monoaminergic theory of depression 18–19

serotonergic syndrome 100

serotonergic syndrome 100, 112

serotonin–norepinephrine reuptake inhibitors (SNRIs) 33, 97

in children 85

in epilepsy 135, 136

in migraine 111

in PD 150

sertraline 99, 136, 185, 199

sexual dysfunction and antidepressants 99, 137, 168

sleep problems 81, 146

SNRIs see serotonin–norepinephrine reuptake inhibitors

spinal cord trauma 58–9

SSRIs see selective serotonin reuptake inhibitors
STAR*D trial (Sequenced Treatment Alternatives to Relieve Depression) 33–4
stem cell therapy 151
stress 11, 17, 129–30, 132
Stroke Aphasic Depression Questionnaire (SADQ) 44
stroke and depression 116–22
case study 121–2
comorbidity 4, 5–6, 43, 116–18
course of the stroke 5–6, 120
diagnosis of PSD 43–4, 119–20
pathogenic mechanisms 118–19
prestroke depression 4, 54, 116–17
prevalence of PSD 43, 116
and suicidality 53–4
symptoms 119
treatment of PSD 120–1
Structured Clinical Interview for DSM-IV Axis 1 Disorders (SCID) 31
substantia nigra 149
subthalamic nucleus (STN) 150–1
suicidality 52–9
after commencing antidepressants 33, 85
and amyotrophic lateral sclerosis 56–7
in children and adolescents 78, 81, 82, 85
and dementia 56
and epilepsy 55–6, 127–8
and Huntington’s disease 55, 147
and migraine 57–8, 106–7, 109
and MS 57, 165, 167–8
and PD 46, 54, 146
risk factors 52–3, 82
screening for 59
and stroke 53–4
and traumatic CNS injuries 58–9, 195–7
sumatriptan 100
synaptic plasticity 20–1
TBI see traumatic brain injury
TCAs see tricyclic antidepressants
temporal lobe epilepsy (TLE)
lobectomy 6, 127
loss of gray matter 133
neurotransmitters 16–17
suicidality 56, 127
thalamus 17
thrombophilia 117
TNF-α (tumor necrosis factor-α) 20–1, 22
topiramate 111, 112, 128
transcranial magnetic stimulation (TMS) 34, 150
traumatic brain injury (TBI) and depression 189–202
case study 201–2
in children 78, 79
course of TBI 197
diagnosis 190, 194
pathogenic mechanisms 79, 197–8
prevalence 190–4
risk factors 198
and suicidality 58, 195–7
symptoms 195
treatment 198–201
traumatic spinal cord injury 58–9
trazodone 199
tricyclic antidepressants (TCAs) 96, 98
cardiac effects 100
in migraine 111–12
in MS 100, 167–8
in PD 150
in TBI 199
triptans 99–100
tumor necrosis factor-α (TNF-α) 20–1, 22
unipolar depressive disorders, definition 29–30
vagus nerve stimulation 34
valproic acid 111, 112
vascular depression 43, 119–20, 181
venlafaxine 33, 85, 111, 150
ventral striatum 149
vijoxazine 96
weight gain 137
white matter abnormalities 24, 79, 120, 162
Zung Scale (ZS) 43